Immunoassay method for human CXCL1 protein

Patent metadata

Field	Value
Publication number	US-9309312-B2
Application number	US-200913126877-A
Country	US
Kind code	B2
Filing date	Oct 29, 2009
Priority date	Oct 31, 2008
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

An object of the present invention is to detect a human CXCL1 protein with high sensitivity. An immunoassay method is provided for a human CXCL1 protein, by which human CXCL1 or a fragment thereof in a sample is measured using two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof, wherein:
each of the two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof specifically recognizes any one of sequence regions of the amino acid sequences shown in SEQ ID NOS: 1-3, which are partial sequences of the amino acid sequence composing a human CXCL1 protein; and the two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof specifically recognize sequence regions that differ from each other.

Monoclonal antibodies or fragments thereof are provided, each of which specifically recognizes any one sequence region of the amino acid sequences shown in SEQ ID NOS: 1-3 and has a new amino acid sequence.

First claim

The invention claimed is:

1. An immunoassay method for measuring a human CXCL1 protein comprising:
contacting the human CXCL1 protein or an antibody-binding fragment thereof in a sample with at least one immobilized first monoclonal antibody or at least one immobilized first antigen-binding fragment thereof, wherein the immobilized first monoclonal antibody or the immobilized first antigen-binding fragment thereof has specificity for at least one epitope region of human CXCL1 protein, wherein the human CXCL1 protein forms a complex with the immobilized first monoclonal antibody or the immobilized first antigen-binding fragment thereof,
adding at least one labeled anti-human CXCL1 monoclonal antibody or at least one labeled antigen-binding fragment thereof, wherein the labeled anti-human CXCL1 monoclonal antibody or the labeled antigen-binding fragment thereof specifically binds an epitope region different from and non-overlapping with that or those bound by the at least one immobilized first antibody or the at least one immobilized first antigen binding fragment thereof and specifically binds with the CXCL1 protein bound in the complex with the at least one immobilized first monoclonal antibody or the at least one immobilized first antigen-binding fragment thereof, and
detecting an amount of signal from the label of the labeled anti-human CXCL1 monoclonal antibody, or the labeled antigen-binding fragment(s) thereof, specifically bound to the antigen-antibody complex(es) as indicative of a level of the human CXCL1 or the antibody-binding fragment thereof in the sample,
wherein the immobilized first monoclonal antibody and the labeled anti-human CXCL1 monoclonal antibody are selected from the group consisting of the following (a) to (e):
(a) an isolated antibody which specifically recognizes the amino acid sequence region shown in SEQ ID NO: 3 that is partial sequence of the amino acid sequence comprising the human CXCL 1 protein, wherein:
in its light chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 4,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 5, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 6;

in its heavy chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 7,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 8, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 9;

(b) an isolated antibody which specifically recognizes the amino acid sequence region shown in SEQ ID NO: 1 that is partial sequence of the amino acid sequence comprising the human CXCL1 protein, wherein:
in its light chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 12,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 13, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 14;

in its heavy chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 15,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 16, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 17;

(c) an isolated antibody which specifically recognizes the amino acid sequence region shown in SEQ ID NO: 3, wherein:
in its light chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 20,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 21, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 22;

in its heavy chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 23,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 24, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 25;

(d) an isolated antibody which specifically recognizes the amino acid sequence region shown in SEQ ID NO: 2 that is partial sequence of the amino acid sequence comprising the human CXCL1 protein, wherein:
in its light chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 28,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 29, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 30;

in its heavy chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 31,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 32, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 33; and

(e) an isolated antibody which specifically recognizes the amino acid sequence region shown in SEQ ID NO: 3, wherein:
in its light chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 36,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 37, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 38;

in its heavy chains,
CDR1 comprises the amino acid sequence shown in SEQ ID NO: 39,
CDR2 comprises the amino acid sequence shown in SEQ ID NO: 40, and
CDR3 comprises the amino acid sequence shown in SEQ ID NO: 41.

2. The immunoassay method for a human CXCL1 protein according to claim 1 , in which the labeled anti-human CXCL1 monoclonal antibody or the labeled antigen-binding fragment thereof specifically recognizes the amino acid sequence region shown in SEQ ID NO: 3.

3. The immunoassay method for a human CXCL1 protein according to claim 1 or 2 , in which the immobilized anti-human CXCL1 monoclonal antibody or the immobilized antigen-binding fragment thereof specifically recognizes the amino acid sequence region shown in SEQ ID NO: 1 and the labeled anti-human CXCL1 monoclonal antibody or the labeled antigen-binding fragment thereof specifically recognizes the amino acid sequence region shown in SEQ ID NO: 3.

4. The immunoassay method for a human CXCL1 protein according to claim 1 or 2 , in which the immobilized anti-human CXCL1 monoclonal antibody or the immobilized antigen-binding fragment thereof specifically recognizes the amino acid sequence region shown in SEQ ID NO: 2 and the labeled anti-human CXCL1 monoclonal antibody or the labeled antigen-binding fragment thereof specifically recognizes the amino acid sequence region shown in SEQ ID NO: 3.

5. The immunoassay method for a human CXCL1 protein according to claim 1 , wherein the sample is a tissue collected after an operation, blood, serum, blood plasma, urine, spinal fluid, saliva, lymph fluid, lacrimal fluid, or seminal fluid.

6. A purified anti-human CXCLI monoclonal antibody or a purified antigen-binding fragment thereof, which specifically recognizes the amino acid sequence region shown in SEQ ID NO: 3, wherein:
in its light chains, CDR1 comprises the amino acid sequence shown in SEQ ID NO: 4, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 5, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 6;
in its heavy chains, CDR1 comprises the amino acid sequence shown in SEQ ID NO: 7, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 8, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 9.

7. The purified anti-human CXCL1 monoclonal antibody or an antigen-binding fragment thereof according to claim 6 , containing the amino acid sequence shown in SEQ ID NO: 10 in a light-chain variable region and the amino acid sequence shown in SEQ ID NO: 11 in a heavy-chain variable region.

8. A purified anti-human CXCL1 monoclonal antibody or a purified antigen-binding fragment thereof, which specifically recognizes the amino acid sequence region shown in SEQ ID NO: 1, wherein:
in its light chains, CDR1 comprises the amino acid sequence shown in SEQ ID NO: 12, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 13, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 14; and
in its heavy chains, CDR1 comprises the amino acid sequence shown in SEQ ID NO: 15, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 16, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 17.

9. The purifie

Assignees

• Kanamori Satoko
• Jung Giman
• Tanaka Yoshinori
• Takayama Aiko
• Toray Industries

Inventors

• Kanamori Satoko
• Jung Giman
• Tanaka Yoshinori
• Takayama Aiko

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• G01N33/543

  with an insoluble carrier for immobilising immunochemicals · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• G01N33/6857

  Antibody fragments · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title